Table 1.
Baseline characteristics among 84 patients receiving MDR-TB treatment.
| Kanamycin (n=44) | Capreomycin (n=40) | p value | |
|---|---|---|---|
| Sex | |||
| Male, n (%) | 33 (75.0) | 29 (72.5) | 0.795a |
| Age (years) | |||
| Mean ± SD | 39 ± 11 | 41 ± 13 | 0.346b |
| Comorbid, n (%) | |||
| Yes | 5 (11.4) | 2 (5.0) | 0.437c |
| No | 39 (88.6) | 38 (95.0) | |
| Concomitant drugs, n (%) | |||
| Yes | 3 (6.8) | 2 (5.0) | 1.000b |
| No | 41 (93.2) | 38 (95.0) | |
| Serum potassium | 4.0 ± 0.4 mEq/L | 4.1 ± 0.5 mEq/L | 0.100b |
| Serum magnesium | 2.33 ± 0.21 mg/dL | 2.23 ± 0.18 mg/dL | 0.082b |
| Serum calcium | 4.80 ± 1.04 mg/dL | 4.74 ± 0.37 mg/dL | 0.839b |
Data are given as mean ± SD or number (%). p values are determined using achi-square test, bt-test, and cFisher's exact test.